https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_anacor
Old news, US5.2b
"...............In both of its Phase 3 pivotal studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and in March 2016, the FDA accepted for review Anacor’s New Drug Application seeking approval of crisaborole for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review is January 7, 2017. If approved, Pfizer believes peak year sales for crisaborole have the potential to reach or exceed $2.0 billion..........”
- Forums
- ASX - By Stock
- BOT
- BOT - Anything but charting
BOT
botanix pharmaceuticals ltd
Add to My Watchlist
9.26%
!
2.5¢
BOT - Anything but charting, page-333
-
Top Stories
- There are more pages in this discussion • 996 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.